Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis

News published by Ionis Pharmaceuticals concerning IONIS-ENAC-2.5 Rx, administered via an optimized eFlow^® Technology nebulizer.
 

Read the press release